



2016 UPDATE: CCS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA
FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE ADULT

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline		
	Consulting fees/ Honoraria	Clinical Trials	Owner, Partner, Officer, Director, Principle or other role/benefit
Primary Panel			
Todd Anderson	Merck	Amgen, Merck	
Jean Grégoire	Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Bristol-Myers Squibb, Merck, Sanofi, Servier, Takeda, Valeant	Amarin, Dal-Cor, Pfizer	
Glen Pearson			
Arden Barry			
Patrick Couture	Amgen, AstraZeneca, Merck, sanofi-aventis	Amgen, Kaneka Corp, Merck, sanofi-aventis	
Martin Dawes		AstraZeneca, Merck, GlaxoSmithKline, Pfizer, Novartis, Roche	GenXys
Gordon Francis	Alexion, Amgen, sanofi-aventis, Valeant	Ionis and The Medicines Company	
Jacques Genest Jr	Amgen, Eli Lilly, Pfizer, sanofi-aventis, Valeant, Aegerion, Kaneka	Amgen, Eli Lilly, Merck, sanofi-aventis	
Steven Grover	Amgen, Merck, Pfizer, sanofi-aventis		McGill Comprehensive Health Improvement Program, Clinemetrica Inc
Milan Gupta	Amgen, Merck, Pfizer, sanofi-aventis, Valeant	Amgen, sanofi-aventis, Valeant	
Robert Hegele	Aegerion, Amgen, Boston Heart Diagnostics, Gemphire, Ionis, Merck, Pfizer, Sanofi-Aventis, Valeant	Aegerion, Amgen, Cerenis, Sanofi-Aventis, Regeneron, Ionis, Medicines Company, Pfizer	



**2016 UPDATE: CCS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA
FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE ADULT**

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline		
	Consulting fees/ Honoraria	Clinical Trials	Owner, Partner, Officer, Director, Principle or other role/benefit
David C W Lau	AstraZeneca, Bristol Myers-Squibb, Boehringer Ingelheim, Merck, Novo Nordisk, Amgen, Janssen, Eli Lilly, Roche, Valeant, Shire		
Lawrence Leiter	Aegerion, Amgen, AstraZeneca, Eli Lilly, Merck, Sanofi	Amgen, AstraZeneca, Eli Lilly, Merck, Pfizer, Sanofi	
Eva Lonn	Amgen, sanofi-aventis	Amgen, Bayer, Eli Lilly, sanofi-aventis	
GB John Mancini	Amgen, Merck, Regeneron, sanofi-aventis		
Ruth McPherson	Amgen, AstraZeneca, Merck, Pfizer, sanofi-aventis	Pfizer	Sanofi- Regeneron
Daniel Ngui	Abbott Vascular, Amgen, AstraZeneca, Bayer, Bristol Myers-Squibb, Boehringer Ingelheim, Merck, Eli Lilly, Novartis, Pfizer		HealthChoicesFirst.ca
Paul Poirier	Abbott Vascular, Amgen, AstraZeneca, Eli Lilly, Boehringer Ingelheim, Merck, Servier, Bristol-Myers Squibb, GlaxoSmithKline, sanofi-aventis	Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Servier	



**2016 UPDATE: CCS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA
FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE ADULT**

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline		
	Consulting fees/ Honoraria	Clinical Trials	Owner, Partner, Officer, Director, Principle or other role/benefit
John L Sievenpiper	Canadian Nutrition Society, Canadian Diabetes Association, University of Alabama at Birmingham, Abbott Laboratories, Nutrition Foundation of Italy, Dairy Farmers of Canada, C3 Collaborating for Health, White Wave Foods, Rippe Lifestyle, mdBriefcase, Dr. Pepper Snapple Group, The Coca-Cola Company, Alberta Milk, FoodMinds, Winston & Strawn LLP, Perkins Coie LLP, Tate & Lyle.	Pfizer, Canadian Institutes of health Research, University of Toronto (through a donation from Tate & Lyle), Canadian Diabetes Association, PSI Foundation, Banting and Best Diabetes Centre, Calorie Control Council, American Society for Nutrition	Toronto 3D Knowledge Synthesis and Clinical Trials foundation
James A Stone	Merck, Forest, Nutradiagnostics		
George Thanassoulis	Servier, Amgen, Ionis		
Richard Ward	AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, GlaxoSmithKline, Otsuka, Pfizer, Servier	AstraZeneca, Cortria, Eli Lilly, Pfizer	
Secondary Panel			
Ranjani Aiyar			
Alexis Baass	Amgen	Amgen, Novartis, Pfizer, sanofi-aventis	
N. John Bosomworth			
Alice Cheng	Amgen, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Eli Lilly, Merck, sanofi-aventis, Servier, Valeant	Amgen, Eli Lilly, Boehringer Ingelheim, sanofi-aventis	



**2016 UPDATE: CCS GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA
FOR THE PREVENTION OF CARDIOVASCULAR DISEASE IN THE ADULT**

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline		
	Consulting fees/ Honoraria	Clinical Trials	Owner, Partner, Officer, Director, Principle or other role/benefit
Dan Dattani	AstraZeneca, Pfizer, Mylan, Bristol-Myers Squibb, Johnson & Johnson, sanofi-aventis	AstraZeneca, Novartis, Johnson & Johnson, PHRI/Timi Group	Portola Pharma shares (held in RSP complied with FDA regulations)
Ross Feldman	Bayer, Servier, Valeant	Bayer	
Robyn Houlden	Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Servier, Johnson & Johnson, sanofi-aventis	Eli Lilly	
Geoff Lewis			
Christopher Naugler	Abbott	Abbott	
Karen Then			
Sheldon Tobe		Abbott Vascular, Bayer, AstraZeneca, Eli Lilly	
Pat Vanderkooy			
Subodh Verma	Abbott, Amgen, AstraZeneca, Bayer,	AstraZeneca, Valeant	